Kamil Sitarz, PhD, MBA is Chief Operating Officer and Management Board Member at Ryvu Therapeutics, where he has played a central role in shaping the company’s evolution from discovery-stage research into a diversified, multi-program clinical oncology organization. He leads enterprise-wide operations spanning clinical development, portfolio and program leadership, capital strategy, partnerships, and organizational scale-up, with responsibility for aligning R&D execution, capital allocation, and long-term corporate priorities. Combining a PhD in Medical Genetics with an Executive MBA, Kamil brings a company-wide perspective to biotech leadership - integrating science, operations, and finance to support strategic growth, investor confidence, and sustained value creation through pivotal clinical and financial milestones.